• Successful dosing of all 30 patients in Phase II clinical trial of RECCE® 327 Topical Gel
• Positive patient data analysis in Phase II clinical trial of R327G for ABSSSI
• Japan Patent Family 4 allowed for Recce's Anti-infectives - expiry 2041
• A$5.0 million placement and A$10.8 million Entitlement Offer to shareholders

Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) released its Q3 FY2025 results and operational highlights. Key points include the successful dosing of all 30 patients in its Phase II clinical trial of R327G for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI), positive patient data analysis in the same trial, the receipt of a notice of allowance from the Japan Patent Office for Patent Family 4 for Recce's Anti-infectives with expiry in 2041, and the hosting of a Key Opinion Leader Clinical Milestones Webinar. The company ended the quarter with a cash balance of $0.2 million and reported net cash outflows from operating activities of ($2.3 million), with Research and Development ($1.2 million) being the largest item of expenditure. Post-quarter, the company announced a successful A$5.0 million placement to an Australian-based private investor and up to ~A$10.8 million 1-for-6 non-renounceable entitlement offer to existing shareholders to raise up to a total of ~A$15.8 million. The company is well-positioned to advance its clinical and operational objectives with the recent funding and non-dilutive funding opportunities.

The company expects a strong pro-forma cash position post the Offer of ~A$16.0 million (before Offer costs), additional estimated R&D rebate of A$8.5 million from the ATO (expected Q4 2025), and anticipated non-dilutive capital via R&D advance of approximately A$10.0 million following completion of the Capital Raising.

The release of positive Phase II clinical trial data provides a strong foundation for the recently approved Registrational Phase 3 DFI trial in Indonesia and expected Phase III Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Registrational Topical Clinical Trial in Australia. Recce is well placed to advance its clinical and operational objectives and is strongly supported by its recent placement and non-renounceable entitlement offer as well as non-dilutive funding opportunities.